CN119110799A - 作为erbb抑制剂的多晶型物 - Google Patents

作为erbb抑制剂的多晶型物 Download PDF

Info

Publication number
CN119110799A
CN119110799A CN202280075401.6A CN202280075401A CN119110799A CN 119110799 A CN119110799 A CN 119110799A CN 202280075401 A CN202280075401 A CN 202280075401A CN 119110799 A CN119110799 A CN 119110799A
Authority
CN
China
Prior art keywords
morphological
morphological form
compound
cancer
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280075401.6A
Other languages
English (en)
Chinese (zh)
Inventor
W-Y·张
R·福鲁吉
S·姜
M·李
J·史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Black Diamond Treatment Co
Original Assignee
Black Diamond Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Black Diamond Treatment Co filed Critical Black Diamond Treatment Co
Publication of CN119110799A publication Critical patent/CN119110799A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280075401.6A 2021-09-21 2022-09-21 作为erbb抑制剂的多晶型物 Pending CN119110799A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246451P 2021-09-21 2021-09-21
US63/246,451 2021-09-21
PCT/US2022/044232 WO2023049168A1 (en) 2021-09-21 2022-09-21 Polymorphs as erbb inhibitors

Publications (1)

Publication Number Publication Date
CN119110799A true CN119110799A (zh) 2024-12-10

Family

ID=83691602

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280075401.6A Pending CN119110799A (zh) 2021-09-21 2022-09-21 作为erbb抑制剂的多晶型物

Country Status (10)

Country Link
US (1) US20240425492A1 (cg-RX-API-DMAC10.html)
EP (1) EP4405350A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024534517A (cg-RX-API-DMAC10.html)
KR (1) KR20240099193A9 (cg-RX-API-DMAC10.html)
CN (1) CN119110799A (cg-RX-API-DMAC10.html)
AU (1) AU2022352658A1 (cg-RX-API-DMAC10.html)
CA (1) CA3231697A1 (cg-RX-API-DMAC10.html)
IL (1) IL311354A (cg-RX-API-DMAC10.html)
MX (1) MX2024003475A (cg-RX-API-DMAC10.html)
WO (1) WO2023049168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2024179451A1 (zh) * 2023-03-02 2024-09-06 江苏康缘药业股份有限公司 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用
WO2025038731A1 (en) * 2023-08-15 2025-02-20 Black Diamond Therapeutics, Inc. Method of treating cancers with alkyne substituted quinazoline derivatives
CN122580302A (zh) * 2023-12-21 2026-08-14 黑钻治疗公司 Erbb抑制剂的固体形式
WO2025137421A1 (en) * 2023-12-21 2025-06-26 Black Diamond Therapeutics, Inc. Compositions comprising alkyne substituted quinazoline derivatives and related uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020328598B2 (en) * 2019-08-15 2026-07-02 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
MX2023004998A (es) * 2020-11-02 2023-05-12 Black Diamond Therapeutics Inc Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.

Also Published As

Publication number Publication date
IL311354A (en) 2024-05-01
EP4405350A1 (en) 2024-07-31
KR20240099193A9 (ko) 2025-12-10
MX2024003475A (es) 2024-04-05
KR20240099193A (ko) 2024-06-28
CA3231697A1 (en) 2023-03-30
AU2022352658A1 (en) 2024-03-21
JP2024534517A (ja) 2024-09-20
US20240425492A1 (en) 2024-12-26
WO2023049168A1 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
US20240425492A1 (en) Polymorphs as erbb inhibitors
US12152034B2 (en) FGFR inhibitors and methods of making and using the same
US12227491B2 (en) EGFR inhibitors
BR112020023107A2 (pt) sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios
JP2025535889A (ja) ピリミジン化合物の新規結晶形態、それを含有する医薬組成物、およびその使用方法
US20260138967A1 (en) The salts of a compound and the crystalline forms thereof
EP3470402B1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
EP4438613A1 (en) Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof
WO2015113521A1 (zh) 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
RS67641B1 (sr) Kristalni oblici derivata hinazolina, njihova priprema, kompozicija i upotreba
US20190263763A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
CN114728875A (zh) 金属盐及其用途
CN121712511A (zh) 用炔烃取代的喹唑啉衍生物治疗癌症的方法
WO2023093859A1 (zh) Axl激酶抑制剂的盐、其制备方法和用途
WO2025137424A1 (en) Solid forms of an erbb inhibitor
EA046831B1 (ru) Соли соединения и их кристаллические формы
EA052616B1 (ru) Кристаллические формы производных хиназолина, их получение, композиции и применение
HK40077267A (en) Metal salts and uses thereof
JP2020513006A (ja) アファチニブジマレアートの新規形態

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination